These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36484532)

  • 1. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
    Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
    ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
    Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
    Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy.
    Liao Y; Zhao C; Pan Y; Guo Y; Liu L; Wu J; Zhang Y; Rao L; Li Q
    Theranostics; 2024; 14(16):6409-6425. PubMed ID: 39431008
    [No Abstract]   [Full Text] [Related]  

  • 6. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
    Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
    Lai X; Yao F; An Y; Li X; Yang XD
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
    Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W
    Cancer Lett; 2020 Apr; 476():170-182. PubMed ID: 32092355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
    Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
    Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
    Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
    J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bispecific Peptide-Polymer Conjugate Bridging Target-Effector Cells to Enhance Immunotherapy.
    Zhang W; Li D; Xu X; Chen Y; Shi X; Pan Y; Yao S; Piao Y; Zhou Z; Slater NKH; Shen Y; Tang J
    Adv Healthc Mater; 2023 Jul; 12(18):e2202977. PubMed ID: 36878223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials.
    Reuss JE; Stern D; Foster JC; Ramaswami R; Lurain K; Chen HX; Streicher H; Kem R; Little RF; Sharon E
    JAMA Netw Open; 2020 Dec; 3(12):e2027110. PubMed ID: 33258905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioorthogonal Activation of TLR7 Agonists Provokes Innate Immunity to Reinforce Aptamer-Based Checkpoint Blockade.
    Wei Y; Qin G; Wang Z; Zhao C; Ren J; Qu X
    ACS Nano; 2023 Mar; 17(6):5808-5820. PubMed ID: 36916491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors.
    Zhang D; Zheng Y; Lin Z; Liu X; Li J; Yang H; Tan W
    Angew Chem Int Ed Engl; 2020 Jul; 59(29):12022-12028. PubMed ID: 32246555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
    Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
    Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review).
    Tang Q; Zhao S; Zhou N; He J; Zu L; Liu T; Song Z; Chen J; Peng L; Xu S
    Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36866750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
    Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
    Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review).
    Hiraga T
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38362963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach.
    Khedri M; Abnous K; Rafatpanah H; Nabavinia MS; Taghdisi SM; Ramezani M
    Immunol Invest; 2020 Jul; 49(5):535-554. PubMed ID: 32429721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.